Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX vs Gemcitabine/Abraxane in Resected Pancreatic Cancer
NCT01839799Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Apr 2013
- Primary completion
- Apr 2017
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of FOLFIRINOX, gemcitabine, nab-paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Abramson Cancer Center. Started Apr 2013; status: completed.
02
Drugs
FOLFIRINOXgemcitabinenab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01839799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01839799.